DCTH

Delcath Systems Inc

Add to Watchlist

Advanced Chart

10.640

+0.12(1.141%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

13.440

Open

12.430

VWAP

11.68

Vol

2.77M

Mkt Cap

370.55M

Low

10.595

Amount

32.37M

EV/EBITDA(TTM)

Total Shares

27.79M

307.48M

EV/OCF(TTM)

P/S(TTM)

6.46

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

28.40M

+88.08%

23.35M

+108.45%

23.02M

+196.39%

Estimates Revision

The market is revising Upward the revenue expectations for Delcath Systems, Inc. (DCTH) for FY2025, with the revenue forecasts being adjusted by 13.75% over the past three months. During the same period, the stock price has changed by -9.22%.

Revenue Estimates for FY2025

Revise Upward

+13.75%

In Past 3 Month

Stock Price

Go Down

-9.22%

In Past 3 Month

5 Analyst Rating

131.20% Upside

Wall Street analysts forecast DCTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCTH is 24.60 USD with a low forecast of 21.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

131.20% Upside

Current: 10.640

Low

21.00

Averages

24.60

High

29.00

131.20% Upside

Current: 10.640

Low

21.00

Averages

24.60

High

29.00

H.C. Wainwright

Buy

maintain

$24 -> $29

2025-05-23

Reason

H.C. Wainwright

Price Target

$24 -> $29

2025-05-23

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Delcath Systems to $29 from $24 and keeps a Buy rating on the shares after the company announced its intention to enter into a Medicaid National Drug Rebate agreement. This strategic move is prudent given that it could not only aid in accessing a larger patient base but also help in achieving sustainable growth, the analyst tells investors in a research note.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Maintains

$22 → $24

2025-03-07

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$22 → $24

2025-03-07

Maintains

Strong Buy

Reason

Craig-Hallum

Chase Knickerbocker

Strong Buy

Maintains

$18 → $21

2025-01-17

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$18 → $21

2025-01-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$22

2025-01-14

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$22

2025-01-14

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$22

2024-11-11

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$22

2024-11-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$22

2024-10-18

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$22

2024-10-18

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Delcath Systems Inc (DCTH.O) is 162.86, compared to its 5-year average forward P/E of -7.31. For a more detailed relative valuation and DCF analysis to assess Delcath Systems Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.31

Current PE

162.86

Overvalued PE

53.96

Undervalued PE

-68.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.98

Current EV/EBITDA

10.55

Overvalued EV/EBITDA

21.05

Undervalued EV/EBITDA

-35.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

16.51

Current PS

3.42

Overvalued PS

32.42

Undervalued PS

0.61